<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03894969</url>
  </required_header>
  <id_info>
    <org_study_id>209538</org_study_id>
    <secondary_id>2018-002977-24</secondary_id>
    <nct_id>NCT03894969</nct_id>
  </id_info>
  <brief_title>Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine</brief_title>
  <official_title>Immunogenicity and Safety Study of GSK's Investigational Vaccine (GSK3277511A) When Administered in Healthy Smokers and Ex-smokers Following Receipt of Shingrix Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide information regarding the sequential administration of two vaccines&#xD;
      adjuvanted with AS01.&#xD;
&#xD;
      The aim of this study is to understand immunogenicity and safety of NTHi-Mcat vaccine when&#xD;
      administered sequentially after Shingrix vaccine and to compare to the immunogenicity of&#xD;
      NTHi-Mcat vaccine administered alone. This study will also provide information regarding&#xD;
      whether a specific time period is required between the administration of these two different&#xD;
      vaccines containing the same adjuvant- AS01 components.&#xD;
&#xD;
      The population of this study will include healthy smokers and ex-smokers of 50 to 80 years of&#xD;
      age which will be used as a proxy for the COPD population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Actual">August 13, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label study. Blinding was not performed on the subjects.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Protein D (PD), Anti-Protein E (PE), Anti-type IV Pili Subunit (PilA) and Anti-ubiquitous Surface Protein A2 of Moraxella Catarrhalis (UspA2) Adjusted Geometric Mean Concentrations (GMCs), One-month Post Dose-2 of NTHi-Mcat Vaccine</measure>
    <time_frame>At 1 month after dose 2 of NTHi-Mcat vaccine (Day 181, in Sh_NTHi-Mcat_1 group and Day 91 in NTHi-Mcat group)</time_frame>
    <description>Antibody concentrations as measured by ELISA (Enzyme-linked immunosorbent assay) and expressed as adjusted (ANCOVA model) GMCs in ELISA units per milliliter (EU/mL). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively. The ANCOVA model includes study group, smoking status (current or former), age category (50-59, 60-69, 70-80 years of age) and center as factors and the antibody concentration before Dose 1 as covariate. As per protocol set (PPS) sample size was not met in Sh_NTHi_Mcat_3 and Sh_NTHi-Mcat_6 groups then timeframe was adapted as follows: At 1 month after dose 2 of NTHi-Mcat vaccine (Day 181 in Sh_NTHi-Mcat_1 group and Day 91 in NTHi-Mcat group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, Before First NTHi-Mcat Vaccine</measure>
    <time_frame>Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 for Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 for NTHi-Mcat group)</time_frame>
    <description>GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, One-month Post Dose-2 of NTHi-Mcat Vaccine</measure>
    <time_frame>At one month after the second dose of NTHi-Mcat vaccine (Day 181, 241, 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)</time_frame>
    <description>GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations) before the first dose of NTHi-Mcat vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Seropositive Subjects for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies Before First NTHi-Mcat Vaccine</measure>
    <time_frame>Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 in the NTHi-Mcat group)</time_frame>
    <description>A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI is defined using the assay lower limit of quantification (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Seropositive for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies, One-month Post Dose-2 of NTHi-Mcat Vaccine</measure>
    <time_frame>At one month after the second dose of NTHi-Mcat vaccine (Day 181, 241, 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)</time_frame>
    <description>A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI are defined using the assay (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Specific Cluster of Differentiation 4 (CD4+) T-cells Against NTHi and Mcat Antigens for Evaluation of Cell-mediated Immune (CMI) Response, Before First Dose of NTHi-Mcat Vaccine</measure>
    <time_frame>Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 in the NTHi-Mcat group)</time_frame>
    <description>Frequency of specific CD4+ T-cells was measured by flow cytometry intracellular cytokine staining (ICS) expressing at least 2 different markers among CD40 Ligand (CD40L), interleukin (IL)-2, IL-13, IL-17, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), upon in vitro stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of CD4+ T-cells Against NTHi and Mcat Antigens for Evaluation of CMI Response, at One-month Post Dose 2 of NTHi-Mcat Vaccine</measure>
    <time_frame>At one month after second dose of NTHi-Mcat vaccine (Day 181, Day 241 and Day 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)</time_frame>
    <description>Frequency of specific CD4+ T-cells was measured by flow cytometry ICS expressing at least 2 different markers among CD40L, IL-2, IL-13, IL-17, TNF-α and IFN-γ, upon in vitro stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Reported Solicited Local Adverse Event (AE)</measure>
    <time_frame>During the 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine</time_frame>
    <description>The percentage of subjects with at least one local solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed local symptoms were pain, redness and swelling. Any local injection site redness/swelling is scored as follows: diameter &gt;=20 milli-meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Reported Solicited General AE</measure>
    <time_frame>During the 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine</time_frame>
    <description>The percentage of subjects with at least one general solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed solicited general symptoms were Fatigue, Gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), Headache, Myalgia, Chills and Fever (oral cavity or axillary route - temperature equal or higher than [&gt;=] 37.5 degrees Celsius [°C])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Any Unsolicited AE</measure>
    <time_frame>During the 30-day follow-up period (i.e. day of vaccination and 29 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine</time_frame>
    <description>An unsolicited adverse event is an adverse event that was not solicited using a Subject Diary and that was spontaneously communicated by a subject who has signed the informed consent. The percentage of subjects with at least one unsolicited AE, regardless of intensity or relationship to vaccination, during the 30-day follow-up period after any NTHi-Mcat vaccine dose are reported for each group. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Any Serious Adverse Event (SAE) During Epoch 001</measure>
    <time_frame>From Day 1 up to and including Day 331 (Epoch 001)</time_frame>
    <description>The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 1 up to and including Day 331, were reported for each group An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Any Potential Immune-mediated Diseases (pIMD's) During Epoch 001</measure>
    <time_frame>From Day 1 up to and including Day 331 (Epoch 001)</time_frame>
    <description>pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Any SAE During Epoch 002</measure>
    <time_frame>From Day 331 up to and including Day 661 (Epoch 002)</time_frame>
    <description>The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 331 up to and including Day 661, are reported for each group. An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, requires hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician. Epoch 2 data analysis is not achieved at the time of the posting. Results will be added when available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Any pIMD's During Epoch 002</measure>
    <time_frame>From Day 331 up to and including Day 661 (Epoch 002)</time_frame>
    <description>pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Epoch 2 data analysis is not achieved at the time of the posting. Results will be added when available.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">542</enrollment>
  <condition>Respiratory Disorders</condition>
  <arm_group>
    <arm_group_label>Sh_NTHi-Mcat_1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sh_NTHi-Mcat_3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sh_NTHi-Mcat_6 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTHi-Mcat Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shingrix-Only Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHI Mcat investigational vaccine. Only safety data were collected for these subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E</intervention_name>
    <description>2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm</description>
    <arm_group_label>NTHi-Mcat Group</arm_group_label>
    <arm_group_label>Sh_NTHi-Mcat_1 Group</arm_group_label>
    <arm_group_label>Sh_NTHi-Mcat_3 Group</arm_group_label>
    <arm_group_label>Sh_NTHi-Mcat_6 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)</intervention_name>
    <description>2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm</description>
    <arm_group_label>Sh_NTHi-Mcat_1 Group</arm_group_label>
    <arm_group_label>Sh_NTHi-Mcat_3 Group</arm_group_label>
    <arm_group_label>Sh_NTHi-Mcat_6 Group</arm_group_label>
    <arm_group_label>Shingrix-Only Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who, in the opinion of the investigator, can and will comply with the&#xD;
             requirements of the protocol (e.g. completion of the diary cards, return for follow-up&#xD;
             visits).&#xD;
&#xD;
          -  Written informed consent obtained from the subject prior to performance of any study&#xD;
             specific procedure.&#xD;
&#xD;
          -  A male or female between, and including, 50 years and 80 years of age at the time of&#xD;
             the first vaccination.&#xD;
&#xD;
          -  Healthy subjects as established by medical history and clinical examination before&#xD;
             entering into the study.&#xD;
&#xD;
          -  Current or former smoker with a cigarette smoking history ≥10 pack-years.&#xD;
&#xD;
          -  Female subjects of non-childbearing potential may be enrolled in the study.&#xD;
             Non-childbearing potential is defined as pre-menarche, current bilateral tubal&#xD;
             ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.&#xD;
&#xD;
          -  Female subjects of childbearing potential may be enrolled in the study, if the&#xD;
             subject: has practiced adequate contraception for 30 days prior to vaccination, and;&#xD;
             has a negative pregnancy test on the day of vaccination, and; has agreed to continue&#xD;
             adequate contraception during the entire treatment period and for 2 months after&#xD;
             completion of the vaccination series.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical conditions&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on&#xD;
             medical history and physical examination (no laboratory testing required).&#xD;
&#xD;
          -  History of potential immune-mediated disease (pIMD). Note: If the subject has any&#xD;
             condition on the list of pIMDs specified in the protocol, they must be excluded unless&#xD;
             the aetiology is clearly documented to be non-immune mediated.&#xD;
&#xD;
        The investigator will exercise his/her medical and scientific judgement in deciding whether&#xD;
        other diseases have an autoimmune origin and thus meet the exclusion criteria.&#xD;
&#xD;
          -  Diagnosis of COPD regardless of severity.&#xD;
&#xD;
          -  History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccines. Additionally, consider allergic reactions to other material or equipment&#xD;
             related to study participation (such as materials that may possibly contain latex&#xD;
             -gloves, syringes, etc).&#xD;
&#xD;
          -  Has significant disease (including significant psychological disorders), in the&#xD;
             opinion of the investigator, likely to interfere with the study and/or likely to cause&#xD;
             death within the study duration.&#xD;
&#xD;
          -  History of or current condition preventing intramuscular injection as bleeding or&#xD;
             coagulation disorder.&#xD;
&#xD;
          -  Malignancies within previous 5 years (excluding non-melanoma skin cancer) or&#xD;
             lymphoproliferative disorders.&#xD;
&#xD;
          -  Prior/concomitant therapy&#xD;
&#xD;
          -  Use of any investigational or non-registered product (drug or vaccine) other than the&#xD;
             study vaccines during the period starting 30 days before the first dose of study&#xD;
             vaccine (Day -29 to Day 1), or planned use during the study period.&#xD;
&#xD;
          -  Planned administration/administration of a vaccine not foreseen by the study protocol&#xD;
             in the period starting 30 days before the first dose and ending 30 days after the last&#xD;
             dose of vaccine administration, with the exception of non-MF59 adjuvanted influenza&#xD;
             vaccines and pneumococcal vaccines which may be administered ≥15 days preceding or&#xD;
             following any study vaccine dose.&#xD;
&#xD;
        Note: For M59 adjuvanted flu vaccine and for any vaccine containing novel adjuvant refer to&#xD;
        exclusion criteria below.&#xD;
&#xD;
          -  Planned administration/administration of a vaccine adjuvanted with the following&#xD;
             adjuvants AS01, AS02, AS03, AS04 and MF59 in the period starting 6 months before the&#xD;
             first dose of study vaccine, and ending at the second blood draw (i.e. approximately 1&#xD;
             month after the administration of the last dose of NTHi-Mcat vaccine). The following&#xD;
             non-exhaustive list should be considered as criteria for exclusion: Prepandrix,&#xD;
             Adjupanrix, Shingrix, Fendrix, Cervarix, FluAd, Chiromas, Gripguard.&#xD;
&#xD;
          -  Previous vaccination with any vaccine containing NTHi and/or Mcat antigens&#xD;
&#xD;
          -  Previous vaccination with Shingrix; (either registered product or participation in a&#xD;
             previous vaccine study).&#xD;
&#xD;
          -  Previous vaccination with HZ live-attenuated vaccine (ZVL)) (either registered product&#xD;
             or participation in a previous vaccine study) within the 2 months of the first study&#xD;
             visit (Day 1).&#xD;
&#xD;
          -  Administration of long-acting immune-modifying drugs at any time during the study&#xD;
             period (e.g. infliximab).&#xD;
&#xD;
          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants&#xD;
             or other immune-modifying drugs during the period starting 6 months prior to the first&#xD;
             vaccine dose, and ending at the second blood draw. (i.e. approximately 1 month after&#xD;
             the administration of the last dose of NTHi-Mcat vaccine). For corticosteroids, this&#xD;
             will mean prednisone ≥5 mg/day (for adult subjects), or equivalent. Only topical&#xD;
             steroids are allowed.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products or plasma derivatives&#xD;
             during the period starting 3 months before the first dose of study vaccine or planned&#xD;
             administration starting from Day 1 and ending at the second blood draw (i.e.&#xD;
             approximately 1 month after the planned administration of the second dose of NTHi-Mcat&#xD;
             vaccine).&#xD;
&#xD;
          -  Prior/concurrent clinical study experience&#xD;
&#xD;
          -  Concurrently participating in another clinical study, at any time during the study&#xD;
             period, in which the subject has been or will be exposed to an investigational or a&#xD;
             non-investigational vaccine/product (drug or medical device).&#xD;
&#xD;
          -  Other exclusions:&#xD;
&#xD;
          -  Pregnant or lactating female,&#xD;
&#xD;
          -  Female planning to become pregnant or planning to discontinue contraceptive&#xD;
             precautions,&#xD;
&#xD;
          -  Current alcoholism and/or drug abuse,&#xD;
&#xD;
          -  Any other clinical condition that, in the opinion of the investigator, might pose&#xD;
             additional risk to the subject due to participation in the study&#xD;
&#xD;
          -  Any study personnel or immediate dependents, family, or household member.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>50106</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jyvaskyla</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>FI-33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rennes cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <results_first_submitted>August 30, 2021</results_first_submitted>
  <results_first_submitted_qc>August 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2021</results_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity</keyword>
  <keyword>Chronic obstructive pulmonary disease (COPD)</keyword>
  <keyword>Non-typeable Haemophilus influenza</keyword>
  <keyword>Moraxella catarrhalis</keyword>
  <keyword>Shingrix</keyword>
  <keyword>Herpes Zoster</keyword>
  <keyword>Adjuvanted vaccines</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03894969/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03894969/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>542 participants were enrolled in the study, but only 541 received at least 1 dose of study treatment (i.e. Shingrix and/or NTHi Mcat vaccine).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sh_NTHi-Mcat_1 Group</title>
          <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
        </group>
        <group group_id="P2">
          <title>Sh_NTHi-Mcat_3 Group</title>
          <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
        </group>
        <group group_id="P3">
          <title>Sh_NTHi-Mcat_6 Group</title>
          <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
        </group>
        <group group_id="P4">
          <title>NTHi-Mcat Group</title>
          <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
        </group>
        <group group_id="P5">
          <title>Shingrix-Only Group</title>
          <description>Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHi Mcat investigational vaccine. Only safety data were collected for these subjects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="135"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="129"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sh_NTHi-Mcat_1 Group</title>
          <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
        </group>
        <group group_id="B2">
          <title>Sh_NTHi-Mcat_3 Group</title>
          <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
        </group>
        <group group_id="B3">
          <title>Sh_NTHi-Mcat_6 Group</title>
          <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
        </group>
        <group group_id="B4">
          <title>NTHi-Mcat Group</title>
          <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
        </group>
        <group group_id="B5">
          <title>Shingrix-Only Group</title>
          <description>Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHi Mcat investigational vaccine. Only safety data were collected for these subjects.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="122"/>
            <count group_id="B4" value="135"/>
            <count group_id="B5" value="16"/>
            <count group_id="B6" value="541"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="7.0"/>
                    <measurement group_id="B2" value="60.9" spread="6.7"/>
                    <measurement group_id="B3" value="60.5" spread="7.1"/>
                    <measurement group_id="B4" value="60.0" spread="7.1"/>
                    <measurement group_id="B5" value="62.4" spread="5.5"/>
                    <measurement group_id="B6" value="60.6" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian Or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="129"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-Protein D (PD), Anti-Protein E (PE), Anti-type IV Pili Subunit (PilA) and Anti-ubiquitous Surface Protein A2 of Moraxella Catarrhalis (UspA2) Adjusted Geometric Mean Concentrations (GMCs), One-month Post Dose-2 of NTHi-Mcat Vaccine</title>
        <description>Antibody concentrations as measured by ELISA (Enzyme-linked immunosorbent assay) and expressed as adjusted (ANCOVA model) GMCs in ELISA units per milliliter (EU/mL). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively. The ANCOVA model includes study group, smoking status (current or former), age category (50-59, 60-69, 70-80 years of age) and center as factors and the antibody concentration before Dose 1 as covariate. As per protocol set (PPS) sample size was not met in Sh_NTHi_Mcat_3 and Sh_NTHi-Mcat_6 groups then timeframe was adapted as follows: At 1 month after dose 2 of NTHi-Mcat vaccine (Day 181 in Sh_NTHi-Mcat_1 group and Day 91 in NTHi-Mcat group)</description>
        <time_frame>At 1 month after dose 2 of NTHi-Mcat vaccine (Day 181, in Sh_NTHi-Mcat_1 group and Day 91 in NTHi-Mcat group)</time_frame>
        <population>Analysis was performed on the per protocol set (PPS) which included all subjects who received full study treatment course to which they were randomized and had post-vaccination immunogenicity data minus subjects with protocol deviations that lead to exclusion.According to protocol,as PPS sample size for Sh_NTHI_Mcat_3 and Sh_NTHI_Mcat_6 Groups was not met,those were not part of the analysis. Shingrix-Only Group was not included in this analysis,as subjects didn't receive the NTHi MCAT vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Sh_NTHi-Mcat_1 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
          </group>
          <group group_id="O2">
            <title>NTHi-Mcat Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Protein D (PD), Anti-Protein E (PE), Anti-type IV Pili Subunit (PilA) and Anti-ubiquitous Surface Protein A2 of Moraxella Catarrhalis (UspA2) Adjusted Geometric Mean Concentrations (GMCs), One-month Post Dose-2 of NTHi-Mcat Vaccine</title>
          <description>Antibody concentrations as measured by ELISA (Enzyme-linked immunosorbent assay) and expressed as adjusted (ANCOVA model) GMCs in ELISA units per milliliter (EU/mL). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively. The ANCOVA model includes study group, smoking status (current or former), age category (50-59, 60-69, 70-80 years of age) and center as factors and the antibody concentration before Dose 1 as covariate. As per protocol set (PPS) sample size was not met in Sh_NTHi_Mcat_3 and Sh_NTHi-Mcat_6 groups then timeframe was adapted as follows: At 1 month after dose 2 of NTHi-Mcat vaccine (Day 181 in Sh_NTHi-Mcat_1 group and Day 91 in NTHi-Mcat group)</description>
          <population>Analysis was performed on the per protocol set (PPS) which included all subjects who received full study treatment course to which they were randomized and had post-vaccination immunogenicity data minus subjects with protocol deviations that lead to exclusion.According to protocol,as PPS sample size for Sh_NTHI_Mcat_3 and Sh_NTHI_Mcat_6 Groups was not met,those were not part of the analysis. Shingrix-Only Group was not included in this analysis,as subjects didn't receive the NTHi MCAT vaccine.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1402.804" lower_limit="1139.194" upper_limit="1727.414"/>
                    <measurement group_id="O2" value="1489.531" lower_limit="1203.846" upper_limit="1843.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6234.827" lower_limit="5053.049" upper_limit="7692.992"/>
                    <measurement group_id="O2" value="7032.52" lower_limit="5666.105" upper_limit="8728.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PilA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1244.373" lower_limit="963.063" upper_limit="1607.854"/>
                    <measurement group_id="O2" value="1089.799" lower_limit="840.246" upper_limit="1413.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-UspA2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1022.961" lower_limit="894.403" upper_limit="1169.998"/>
                    <measurement group_id="O2" value="941.45" lower_limit="820.993" upper_limit="1079.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>To demonstrate the non-inferiority (NI) of the humoral immune response 1 month after Dose 2 of GSK Biologicals' NTHi-Mcat investigational vaccine when administered 1 after Shingrix vaccine versus the humoral immune response 1 month after Dose 2 of GSKBiologicals' NTHi-Mcat investigational vaccine alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is concluded if the lower limit of the two sided 95% CI for the GMC ratio for anti-PD is &gt; 0.667. The anti-PD GMC ratio is presented in this test with its 95% CI.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.942</param_value>
            <ci_percent>.95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.765</ci_lower_limit>
            <ci_upper_limit>1.159</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>To demonstrate the non-inferiority (NI) of the humoral immune response 1 month after Dose 2 of GSK Biologicals' NTHi-Mcat investigational vaccine when administered 1 after Shingrix vaccine versus the humoral immune response 1 month after Dose 2 of GSKBiologicals' NTHi-Mcat investigational vaccine alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is concluded if the lower limit of the two sided 95% CI for the GMC ratio for anti-PE is &gt; 0.667. The anti-PE GMC ratio is presented in this test with its 95% CI.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.887</param_value>
            <ci_percent>.95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.719</ci_lower_limit>
            <ci_upper_limit>1.093</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>To demonstrate the non-inferiority (NI) of the humoral immune response 1 month after Dose 2 of GSK Biologicals' NTHi-Mcat investigational vaccine when administered 1 after Shingrix vaccine versus the humoral immune response 1 month after Dose 2 of GSKBiologicals' NTHi-Mcat investigational vaccine alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is concluded if the lower limit of the two sided 95% CI for the GMC ratio for anti-PilA is &gt; 0.667. The anti-PilA GMC ratio is presented in this test with its 95% CI.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.142</param_value>
            <ci_percent>.95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.884</ci_lower_limit>
            <ci_upper_limit>1.474</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>To demonstrate the non-inferiority (NI) of the humoral immune response 1 month after Dose 2 of GSK Biologicals' NTHi-Mcat investigational vaccine when administered 1 after Shingrix vaccine versus the humoral immune response 1 month after Dose 2 of GSKBiologicals' NTHi-Mcat investigational vaccine alone.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is concluded if the lower limit of the two sided 95% CI for the GMC ratio for anti-UspA2 is &gt; 0.667. The anti-UspA2 GMC ratio is presented in this test with its 95% CI.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.087</param_value>
            <ci_percent>.95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.948</ci_lower_limit>
            <ci_upper_limit>1.245</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, Before First NTHi-Mcat Vaccine</title>
        <description>GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations)</description>
        <time_frame>Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 for Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 for NTHi-Mcat group)</time_frame>
        <population>Analysis was performed on the PPS which included all subjects who received full study treatment course to which they were randomized and had post-vaccination immunogenicity data minus subjects with protocol deviations that lead to exclusion. Subjects from the Shingrix-Only Group were not included in this analysis, as they didn't receive the NTHi MCAT vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Sh_NTHi-Mcat_1 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
          </group>
          <group group_id="O2">
            <title>Sh_NTHi-Mcat_3 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
          </group>
          <group group_id="O3">
            <title>Sh_NTHi-Mcat_6 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
          </group>
          <group group_id="O4">
            <title>NTHi-Mcat Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, Before First NTHi-Mcat Vaccine</title>
          <description>GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations)</description>
          <population>Analysis was performed on the PPS which included all subjects who received full study treatment course to which they were randomized and had post-vaccination immunogenicity data minus subjects with protocol deviations that lead to exclusion. Subjects from the Shingrix-Only Group were not included in this analysis, as they didn't receive the NTHi MCAT vaccine.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="86.2" upper_limit="104.1"/>
                    <measurement group_id="O2" value="105.1" lower_limit="89.8" upper_limit="123"/>
                    <measurement group_id="O3" value="95.6" lower_limit="84.5" upper_limit="108.3"/>
                    <measurement group_id="O4" value="105.3" lower_limit="93.4" upper_limit="118.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="18" upper_limit="26.9"/>
                    <measurement group_id="O2" value="21.2" lower_limit="17.6" upper_limit="25.4"/>
                    <measurement group_id="O3" value="18.6" lower_limit="14.3" upper_limit="24.2"/>
                    <measurement group_id="O4" value="23.9" lower_limit="19.8" upper_limit="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PilA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="6.6" upper_limit="9.3"/>
                    <measurement group_id="O2" value="10.5" lower_limit="8.2" upper_limit="13.5"/>
                    <measurement group_id="O3" value="9.7" lower_limit="7.5" upper_limit="12.6"/>
                    <measurement group_id="O4" value="9.1" lower_limit="7.5" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-UspA2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352.4" lower_limit="292.5" upper_limit="424.7"/>
                    <measurement group_id="O2" value="343" lower_limit="286.3" upper_limit="411"/>
                    <measurement group_id="O3" value="440.3" lower_limit="343.5" upper_limit="564.5"/>
                    <measurement group_id="O4" value="521.4" lower_limit="441" upper_limit="616.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, One-month Post Dose-2 of NTHi-Mcat Vaccine</title>
        <description>GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations) before the first dose of NTHi-Mcat vaccine</description>
        <time_frame>At one month after the second dose of NTHi-Mcat vaccine (Day 181, 241, 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)</time_frame>
        <population>Analysis was performed on the PPS which included all subjects who received full study treatment course to which they were randomized and had post-vaccination immunogenicity data minus subjects with protocol deviations that lead to exclusion. Subjects from the Shingrix-Only Group were not included in this analysis, as they didn't receive the NTHi MCAT vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Sh_NTHi-Mcat_1 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
          </group>
          <group group_id="O2">
            <title>Sh_NTHi-Mcat_3 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
          </group>
          <group group_id="O3">
            <title>Sh_NTHi-Mcat_6 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
          </group>
          <group group_id="O4">
            <title>NTHi-Mcat Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, One-month Post Dose-2 of NTHi-Mcat Vaccine</title>
          <description>GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations) before the first dose of NTHi-Mcat vaccine</description>
          <population>Analysis was performed on the PPS which included all subjects who received full study treatment course to which they were randomized and had post-vaccination immunogenicity data minus subjects with protocol deviations that lead to exclusion. Subjects from the Shingrix-Only Group were not included in this analysis, as they didn't receive the NTHi MCAT vaccine.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1496.7" lower_limit="1272.7" upper_limit="1760.1"/>
                    <measurement group_id="O2" value="1504" lower_limit="1209.9" upper_limit="1869.6"/>
                    <measurement group_id="O3" value="1539" lower_limit="1277.3" upper_limit="1854.2"/>
                    <measurement group_id="O4" value="1683.5" lower_limit="1434.5" upper_limit="1975.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5911.8" lower_limit="5121.3" upper_limit="6824.3"/>
                    <measurement group_id="O2" value="5920.8" lower_limit="4868.4" upper_limit="7200.8"/>
                    <measurement group_id="O3" value="6048.5" lower_limit="4943.3" upper_limit="7400.8"/>
                    <measurement group_id="O4" value="6562.4" lower_limit="5660.9" upper_limit="7607.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PilA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1089.3" lower_limit="910.3" upper_limit="1303.4"/>
                    <measurement group_id="O2" value="1030.6" lower_limit="839.4" upper_limit="1265.3"/>
                    <measurement group_id="O3" value="1114.7" lower_limit="864.9" upper_limit="1436.6"/>
                    <measurement group_id="O4" value="999.3" lower_limit="830.3" upper_limit="1202.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-UspA2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="926.8" lower_limit="796.6" upper_limit="1078.4"/>
                    <measurement group_id="O2" value="942.2" lower_limit="819.6" upper_limit="1083.2"/>
                    <measurement group_id="O3" value="1289.2" lower_limit="1062.5" upper_limit="1564.5"/>
                    <measurement group_id="O4" value="1066.4" lower_limit="946.6" upper_limit="1201.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Seropositive Subjects for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies Before First NTHi-Mcat Vaccine</title>
        <description>A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI is defined using the assay lower limit of quantification (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively</description>
        <time_frame>Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 in the NTHi-Mcat group)</time_frame>
        <population>Analysis was performed on the PPS which included all subjects who received full study treatment course to which they were randomized and had post-vaccination immunogenicity data minus subjects with protocol deviations that lead to exclusion. Subjects from the Shingrix-Only Group were not included in this analysis, as they didn't receive the NTHi MCAT vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Sh_NTHi-Mcat_1 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
          </group>
          <group group_id="O2">
            <title>Sh_NTHi-Mcat_3 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
          </group>
          <group group_id="O3">
            <title>Sh_NTHi-Mcat_6 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
          </group>
          <group group_id="O4">
            <title>NTHi-Mcat Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Seropositive Subjects for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies Before First NTHi-Mcat Vaccine</title>
          <description>A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI is defined using the assay lower limit of quantification (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively</description>
          <population>Analysis was performed on the PPS which included all subjects who received full study treatment course to which they were randomized and had post-vaccination immunogenicity data minus subjects with protocol deviations that lead to exclusion. Subjects from the Shingrix-Only Group were not included in this analysis, as they didn't receive the NTHi MCAT vaccine.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="10.7" upper_limit="25"/>
                    <measurement group_id="O2" value="20" lower_limit="12.5" upper_limit="29.5"/>
                    <measurement group_id="O3" value="19.2" lower_limit="10.9" upper_limit="30.1"/>
                    <measurement group_id="O4" value="21.8" lower_limit="14.9" upper_limit="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6" lower_limit="48.2" upper_limit="66.7"/>
                    <measurement group_id="O2" value="63.5" lower_limit="53.1" upper_limit="73.1"/>
                    <measurement group_id="O3" value="50.7" lower_limit="38.7" upper_limit="62.6"/>
                    <measurement group_id="O4" value="61.8" lower_limit="52.6" upper_limit="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PilA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="29.4" upper_limit="47.5"/>
                    <measurement group_id="O2" value="49" lower_limit="38.6" upper_limit="59.4"/>
                    <measurement group_id="O3" value="47.9" lower_limit="36.1" upper_limit="60"/>
                    <measurement group_id="O4" value="43.5" lower_limit="34.7" upper_limit="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-UspA2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.9" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96.2" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95.1" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="97.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Seropositive for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies, One-month Post Dose-2 of NTHi-Mcat Vaccine</title>
        <description>A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI are defined using the assay (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively</description>
        <time_frame>At one month after the second dose of NTHi-Mcat vaccine (Day 181, 241, 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)</time_frame>
        <population>Analysis was performed on the PPS which included all subjects who received full study treatment course to which they were randomized and had post-vaccination immunogenicity data minus subjects with protocol deviations that lead to exclusion. Subjects from the Shingrix-Only Group were not included in this analysis, as they didn't receive the NTHi MCAT vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Sh_NTHi-Mcat_1 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
          </group>
          <group group_id="O2">
            <title>Sh_NTHi-Mcat_3 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
          </group>
          <group group_id="O3">
            <title>Sh_NTHi-Mcat_6 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
          </group>
          <group group_id="O4">
            <title>NTHi-Mcat Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Seropositive for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies, One-month Post Dose-2 of NTHi-Mcat Vaccine</title>
          <description>A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI are defined using the assay (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively</description>
          <population>Analysis was performed on the PPS which included all subjects who received full study treatment course to which they were randomized and had post-vaccination immunogenicity data minus subjects with protocol deviations that lead to exclusion. Subjects from the Shingrix-Only Group were not included in this analysis, as they didn't receive the NTHi MCAT vaccine.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="95.4" upper_limit="100"/>
                    <measurement group_id="O2" value="97.9" lower_limit="92.7" upper_limit="99.7"/>
                    <measurement group_id="O3" value="100" lower_limit="95.1" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.9" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96.2" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95.1" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="97.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PilA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.9" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96.2" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95.1" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="97.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-UspA2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.9" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96.2" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95.1" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="97.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Specific Cluster of Differentiation 4 (CD4+) T-cells Against NTHi and Mcat Antigens for Evaluation of Cell-mediated Immune (CMI) Response, Before First Dose of NTHi-Mcat Vaccine</title>
        <description>Frequency of specific CD4+ T-cells was measured by flow cytometry intracellular cytokine staining (ICS) expressing at least 2 different markers among CD40 Ligand (CD40L), interleukin (IL)-2, IL-13, IL-17, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), upon in vitro stimulation</description>
        <time_frame>Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 in the NTHi-Mcat group)</time_frame>
        <population>Analysis was performed on Cell-Mediated immune (CMI) sub-cohort, which included approximately 60 subjects (15/each group), for which an additional blood sample was taken at each pre-defined timepoint (sub-cohort selected from sites able to process the blood samples according to GSK procedures for peripheral blood mononuclear cell preparation). Subjects from the Shingrix-Only Group were not included in this analysis, as they didn't receive the NTHi MCAT vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Sh_NTHi-Mcat_1 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
          </group>
          <group group_id="O2">
            <title>Sh_NTHi-Mcat_3 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
          </group>
          <group group_id="O3">
            <title>Sh_NTHi-Mcat_6 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
          </group>
          <group group_id="O4">
            <title>NTHi-Mcat Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Specific Cluster of Differentiation 4 (CD4+) T-cells Against NTHi and Mcat Antigens for Evaluation of Cell-mediated Immune (CMI) Response, Before First Dose of NTHi-Mcat Vaccine</title>
          <description>Frequency of specific CD4+ T-cells was measured by flow cytometry intracellular cytokine staining (ICS) expressing at least 2 different markers among CD40 Ligand (CD40L), interleukin (IL)-2, IL-13, IL-17, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), upon in vitro stimulation</description>
          <population>Analysis was performed on Cell-Mediated immune (CMI) sub-cohort, which included approximately 60 subjects (15/each group), for which an additional blood sample was taken at each pre-defined timepoint (sub-cohort selected from sites able to process the blood samples according to GSK procedures for peripheral blood mononuclear cell preparation). Subjects from the Shingrix-Only Group were not included in this analysis, as they didn't receive the NTHi MCAT vaccine.</population>
          <units>CD4+ T cells/million cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M catarrhalis.UspA2 - CD4+ T-cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.945" spread="153.903"/>
                    <measurement group_id="O2" value="101.739" spread="94.932"/>
                    <measurement group_id="O3" value="81.578" spread="90.919"/>
                    <measurement group_id="O4" value="92.685" spread="99.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTHi.PD - CD4+ T-cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.456" spread="68.929"/>
                    <measurement group_id="O2" value="59.522" spread="82.06"/>
                    <measurement group_id="O3" value="36.439" spread="57.347"/>
                    <measurement group_id="O4" value="96.893" spread="74.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTHi.PE - CD4+ T-cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.838" spread="58.999"/>
                    <measurement group_id="O2" value="46.112" spread="63.007"/>
                    <measurement group_id="O3" value="69.546" spread="97.09"/>
                    <measurement group_id="O4" value="80.717" spread="119.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTHi.PilA - CD4+ T-cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.627" spread="53.613"/>
                    <measurement group_id="O2" value="42.438" spread="55.575"/>
                    <measurement group_id="O3" value="60.139" spread="51.37"/>
                    <measurement group_id="O4" value="105.558" spread="97.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of CD4+ T-cells Against NTHi and Mcat Antigens for Evaluation of CMI Response, at One-month Post Dose 2 of NTHi-Mcat Vaccine</title>
        <description>Frequency of specific CD4+ T-cells was measured by flow cytometry ICS expressing at least 2 different markers among CD40L, IL-2, IL-13, IL-17, TNF-α and IFN-γ, upon in vitro stimulation</description>
        <time_frame>At one month after second dose of NTHi-Mcat vaccine (Day 181, Day 241 and Day 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)</time_frame>
        <population>Analysis was performed on CMI sub-cohort, which included approximately 60 subjects (15/each group), for which an additional blood sample was taken at each pre-defined time point (sub-cohort selected from sites able to process the blood samples according to GSK procedures for peripheral blood mononuclear cell preparation). Subjects from the Shingrix-Only Group were not included in this analysis, as they didn't receive the NTHi MCAT vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Sh_NTHi-Mcat_1 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
          </group>
          <group group_id="O2">
            <title>Sh_NTHi-Mcat_3 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
          </group>
          <group group_id="O3">
            <title>Sh_NTHi-Mcat_6 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
          </group>
          <group group_id="O4">
            <title>NTHi-Mcat Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD4+ T-cells Against NTHi and Mcat Antigens for Evaluation of CMI Response, at One-month Post Dose 2 of NTHi-Mcat Vaccine</title>
          <description>Frequency of specific CD4+ T-cells was measured by flow cytometry ICS expressing at least 2 different markers among CD40L, IL-2, IL-13, IL-17, TNF-α and IFN-γ, upon in vitro stimulation</description>
          <population>Analysis was performed on CMI sub-cohort, which included approximately 60 subjects (15/each group), for which an additional blood sample was taken at each pre-defined time point (sub-cohort selected from sites able to process the blood samples according to GSK procedures for peripheral blood mononuclear cell preparation). Subjects from the Shingrix-Only Group were not included in this analysis, as they didn't receive the NTHi MCAT vaccine.</population>
          <units>CD4+ T cells/million cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M catarrhalis.UspA2 - CD4+ T-cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="721.851" spread="457.94"/>
                    <measurement group_id="O2" value="619.68" spread="392.133"/>
                    <measurement group_id="O3" value="1001.839" spread="144.057"/>
                    <measurement group_id="O4" value="735.177" spread="471.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTHi.PD - CD4+ T-cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632.849" spread="323.731"/>
                    <measurement group_id="O2" value="527.26" spread="281.827"/>
                    <measurement group_id="O3" value="1570.631" spread="1064.327"/>
                    <measurement group_id="O4" value="742.666" spread="527.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTHi.PE - CD4+ T-cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="565.964" spread="411.715"/>
                    <measurement group_id="O2" value="581.338" spread="520.594"/>
                    <measurement group_id="O3" value="888.057" spread="154.524"/>
                    <measurement group_id="O4" value="1155.341" spread="699.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTHi.PilA - CD4+ T-cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332.43" spread="273.215"/>
                    <measurement group_id="O2" value="318.46" spread="195.527"/>
                    <measurement group_id="O3" value="333.501" spread="121.712"/>
                    <measurement group_id="O4" value="388.282" spread="207.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Reported Solicited Local Adverse Event (AE)</title>
        <description>The percentage of subjects with at least one local solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed local symptoms were pain, redness and swelling. Any local injection site redness/swelling is scored as follows: diameter &gt;=20 milli-meters</description>
        <time_frame>During the 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine</time_frame>
        <population>Analysis was performed on the Solicited safety set (SSS) which included all subjects who received at least 1 dose of the study treatment and who have solicited safety data</population>
        <group_list>
          <group group_id="O1">
            <title>Sh_NTHi-Mcat_1 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
          </group>
          <group group_id="O2">
            <title>Sh_NTHi-Mcat_3 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
          </group>
          <group group_id="O3">
            <title>Sh_NTHi-Mcat_6 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
          </group>
          <group group_id="O4">
            <title>NTHi-Mcat Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Reported Solicited Local Adverse Event (AE)</title>
          <description>The percentage of subjects with at least one local solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed local symptoms were pain, redness and swelling. Any local injection site redness/swelling is scored as follows: diameter &gt;=20 milli-meters</description>
          <population>Analysis was performed on the Solicited safety set (SSS) which included all subjects who received at least 1 dose of the study treatment and who have solicited safety data</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema (mm), Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="2.6" upper_limit="11.4"/>
                    <measurement group_id="O2" value="15" lower_limit="9.4" upper_limit="22.3"/>
                    <measurement group_id="O3" value="11" lower_limit="6" upper_limit="18.1"/>
                    <measurement group_id="O4" value="12.6" lower_limit="7.5" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (mm), Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="117"/>
                    <count group_id="O4" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="7.6" upper_limit="19.7"/>
                    <measurement group_id="O2" value="13.7" lower_limit="8.4" upper_limit="20.8"/>
                    <measurement group_id="O3" value="17.9" lower_limit="11.5" upper_limit="26.1"/>
                    <measurement group_id="O4" value="11.8" lower_limit="6.8" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7" lower_limit="50.9" upper_limit="68.1"/>
                    <measurement group_id="O2" value="69.2" lower_limit="60.6" upper_limit="76.9"/>
                    <measurement group_id="O3" value="61" lower_limit="51.6" upper_limit="69.9"/>
                    <measurement group_id="O4" value="63.7" lower_limit="55" upper_limit="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="117"/>
                    <count group_id="O4" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" lower_limit="61.4" upper_limit="77.6"/>
                    <measurement group_id="O2" value="76.3" lower_limit="68.1" upper_limit="83.3"/>
                    <measurement group_id="O3" value="72.6" lower_limit="63.6" upper_limit="80.5"/>
                    <measurement group_id="O4" value="75.6" lower_limit="67.2" upper_limit="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (mm), Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="1.2" upper_limit="8.5"/>
                    <measurement group_id="O2" value="10.5" lower_limit="5.9" upper_limit="17"/>
                    <measurement group_id="O3" value="5.9" lower_limit="2.4" upper_limit="11.8"/>
                    <measurement group_id="O4" value="5.2" lower_limit="2.1" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (mm), Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="117"/>
                    <count group_id="O4" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="3.7" upper_limit="13.4"/>
                    <measurement group_id="O2" value="8.4" lower_limit="4.3" upper_limit="14.5"/>
                    <measurement group_id="O3" value="6.8" lower_limit="3" upper_limit="13"/>
                    <measurement group_id="O4" value="7.9" lower_limit="3.8" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Reported Solicited General AE</title>
        <description>The percentage of subjects with at least one general solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed solicited general symptoms were Fatigue, Gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), Headache, Myalgia, Chills and Fever (oral cavity or axillary route - temperature equal or higher than [&gt;=] 37.5 degrees Celsius [°C])</description>
        <time_frame>During the 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine</time_frame>
        <population>Analysis was performed on the SSS which included all subjects who received at least 1 dose of the study treatment and who have solicited safety data</population>
        <group_list>
          <group group_id="O1">
            <title>Sh_NTHi-Mcat_1 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
          </group>
          <group group_id="O2">
            <title>Sh_NTHi-Mcat_3 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
          </group>
          <group group_id="O3">
            <title>Sh_NTHi-Mcat_6 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
          </group>
          <group group_id="O4">
            <title>NTHi-Mcat Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Reported Solicited General AE</title>
          <description>The percentage of subjects with at least one general solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed solicited general symptoms were Fatigue, Gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), Headache, Myalgia, Chills and Fever (oral cavity or axillary route - temperature equal or higher than [&gt;=] 37.5 degrees Celsius [°C])</description>
          <population>Analysis was performed on the SSS which included all subjects who received at least 1 dose of the study treatment and who have solicited safety data</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chills, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="7" upper_limit="18.7"/>
                    <measurement group_id="O2" value="12" lower_limit="7" upper_limit="18.8"/>
                    <measurement group_id="O3" value="16.9" lower_limit="10.7" upper_limit="25"/>
                    <measurement group_id="O4" value="7.4" lower_limit="3.6" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="117"/>
                    <count group_id="O4" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="18.4" upper_limit="33.8"/>
                    <measurement group_id="O2" value="26" lower_limit="18.7" upper_limit="34.3"/>
                    <measurement group_id="O3" value="22.2" lower_limit="15.1" upper_limit="30.8"/>
                    <measurement group_id="O4" value="16.5" lower_limit="10.5" upper_limit="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="18.9" upper_limit="34.4"/>
                    <measurement group_id="O2" value="38.3" lower_limit="30.1" upper_limit="47.2"/>
                    <measurement group_id="O3" value="39" lower_limit="30.1" upper_limit="48.4"/>
                    <measurement group_id="O4" value="34.1" lower_limit="26.1" upper_limit="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="117"/>
                    <count group_id="O4" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="30.8" upper_limit="47.9"/>
                    <measurement group_id="O2" value="48.1" lower_limit="39.3" upper_limit="57"/>
                    <measurement group_id="O3" value="43.6" lower_limit="34.4" upper_limit="53.1"/>
                    <measurement group_id="O4" value="37.8" lower_limit="29.3" upper_limit="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (C), Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.2" upper_limit="5.3"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.2" upper_limit="5.3"/>
                    <measurement group_id="O3" value="2.5" lower_limit="0.5" upper_limit="7.3"/>
                    <measurement group_id="O4" value="3" lower_limit="0.8" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (C), Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="117"/>
                    <count group_id="O4" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="6.5" upper_limit="17.9"/>
                    <measurement group_id="O2" value="8.4" lower_limit="4.3" upper_limit="14.5"/>
                    <measurement group_id="O3" value="8.5" lower_limit="4.2" upper_limit="15.2"/>
                    <measurement group_id="O4" value="8.7" lower_limit="4.4" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="8.2" upper_limit="20.4"/>
                    <measurement group_id="O2" value="13.5" lower_limit="8.2" upper_limit="20.5"/>
                    <measurement group_id="O3" value="16.1" lower_limit="10" upper_limit="24"/>
                    <measurement group_id="O4" value="13.3" lower_limit="8.1" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="117"/>
                    <count group_id="O4" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="10" upper_limit="23.1"/>
                    <measurement group_id="O2" value="15.3" lower_limit="9.6" upper_limit="22.6"/>
                    <measurement group_id="O3" value="12.8" lower_limit="7.4" upper_limit="20.3"/>
                    <measurement group_id="O4" value="9.4" lower_limit="5" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" lower_limit="14.4" upper_limit="28.8"/>
                    <measurement group_id="O2" value="26.3" lower_limit="19.1" upper_limit="34.7"/>
                    <measurement group_id="O3" value="22.9" lower_limit="15.7" upper_limit="31.5"/>
                    <measurement group_id="O4" value="18.5" lower_limit="12.4" upper_limit="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="117"/>
                    <count group_id="O4" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="24.5" upper_limit="41"/>
                    <measurement group_id="O2" value="38.2" lower_limit="29.8" upper_limit="47.1"/>
                    <measurement group_id="O3" value="23.9" lower_limit="16.5" upper_limit="32.7"/>
                    <measurement group_id="O4" value="22" lower_limit="15.2" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="13.7" upper_limit="27.9"/>
                    <measurement group_id="O2" value="23.3" lower_limit="16.4" upper_limit="31.4"/>
                    <measurement group_id="O3" value="25.4" lower_limit="17.9" upper_limit="34.3"/>
                    <measurement group_id="O4" value="27.4" lower_limit="20.1" upper_limit="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="117"/>
                    <count group_id="O4" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" lower_limit="25.2" upper_limit="41.8"/>
                    <measurement group_id="O2" value="37.4" lower_limit="29.1" upper_limit="46.3"/>
                    <measurement group_id="O3" value="36.8" lower_limit="28" upper_limit="46.2"/>
                    <measurement group_id="O4" value="37.8" lower_limit="29.3" upper_limit="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Any Unsolicited AE</title>
        <description>An unsolicited adverse event is an adverse event that was not solicited using a Subject Diary and that was spontaneously communicated by a subject who has signed the informed consent. The percentage of subjects with at least one unsolicited AE, regardless of intensity or relationship to vaccination, during the 30-day follow-up period after any NTHi-Mcat vaccine dose are reported for each group. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event</description>
        <time_frame>During the 30-day follow-up period (i.e. day of vaccination and 29 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine</time_frame>
        <population>Analysis was performed on the Unsolicited safety set which included all subjects who receive at least 1 dose of the study treatment and who have unsolicited safety data</population>
        <group_list>
          <group group_id="O1">
            <title>Sh_NTHi-Mcat_1 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
          </group>
          <group group_id="O2">
            <title>Sh_NTHi-Mcat_3 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
          </group>
          <group group_id="O3">
            <title>Sh_NTHi-Mcat_6 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
          </group>
          <group group_id="O4">
            <title>NTHi-Mcat Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Any Unsolicited AE</title>
          <description>An unsolicited adverse event is an adverse event that was not solicited using a Subject Diary and that was spontaneously communicated by a subject who has signed the informed consent. The percentage of subjects with at least one unsolicited AE, regardless of intensity or relationship to vaccination, during the 30-day follow-up period after any NTHi-Mcat vaccine dose are reported for each group. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event</description>
          <population>Analysis was performed on the Unsolicited safety set which included all subjects who receive at least 1 dose of the study treatment and who have unsolicited safety data</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="122"/>
                <count group_id="O4" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="122"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="8.2" upper_limit="20.4"/>
                    <measurement group_id="O2" value="14.9" lower_limit="9.4" upper_limit="22.1"/>
                    <measurement group_id="O3" value="11.5" lower_limit="6.4" upper_limit="18.5"/>
                    <measurement group_id="O4" value="18.5" lower_limit="12.4" upper_limit="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="9.4" upper_limit="22.3"/>
                    <measurement group_id="O2" value="15.3" lower_limit="9.6" upper_limit="22.6"/>
                    <measurement group_id="O3" value="8.5" lower_limit="4.1" upper_limit="15"/>
                    <measurement group_id="O4" value="10.9" lower_limit="6.1" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Any Serious Adverse Event (SAE) During Epoch 001</title>
        <description>The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 1 up to and including Day 331, were reported for each group An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician</description>
        <time_frame>From Day 1 up to and including Day 331 (Epoch 001)</time_frame>
        <population>Analysis was performed on the Exposed Set (ES) which included all subjects who received at least 1 dose of the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sh_NTHi-Mcat_1 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
          </group>
          <group group_id="O2">
            <title>Sh_NTHi-Mcat_3 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
          </group>
          <group group_id="O3">
            <title>Sh_NTHi-Mcat_6 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
          </group>
          <group group_id="O4">
            <title>NTHi-Mcat Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
          </group>
          <group group_id="O5">
            <title>Shingrix-Only Group</title>
            <description>Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHi Mcat investigational vaccine. Only safety data were collected for these subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Any Serious Adverse Event (SAE) During Epoch 001</title>
          <description>The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 1 up to and including Day 331, were reported for each group An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician</description>
          <population>Analysis was performed on the Exposed Set (ES) which included all subjects who received at least 1 dose of the study treatment.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="122"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="1.7" upper_limit="9.5"/>
                    <measurement group_id="O2" value="3.7" lower_limit="1.2" upper_limit="8.5"/>
                    <measurement group_id="O3" value="2.5" lower_limit="0.5" upper_limit="7"/>
                    <measurement group_id="O4" value="1.5" lower_limit="0.2" upper_limit="5.2"/>
                    <measurement group_id="O5" value="6.3" lower_limit="0.2" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Any Potential Immune-mediated Diseases (pIMD's) During Epoch 001</title>
        <description>pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
        <time_frame>From Day 1 up to and including Day 331 (Epoch 001)</time_frame>
        <population>Analysis was performed on the ES which included all subjects who received at least 1 dose of the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sh_NTHi-Mcat_1 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
          </group>
          <group group_id="O2">
            <title>Sh_NTHi-Mcat_3 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
          </group>
          <group group_id="O3">
            <title>Sh_NTHi-Mcat_6 Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
          </group>
          <group group_id="O4">
            <title>NTHi-Mcat Group</title>
            <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
          </group>
          <group group_id="O5">
            <title>Shingrix-Only Group</title>
            <description>Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHi Mcat investigational vaccine. Only safety data were collected for these subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Any Potential Immune-mediated Diseases (pIMD's) During Epoch 001</title>
          <description>pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
          <population>Analysis was performed on the ES which included all subjects who received at least 1 dose of the study treatment.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="122"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2.7"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.2" upper_limit="5.3"/>
                    <measurement group_id="O3" value="0.8" lower_limit="0" upper_limit="4.5"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="2.7"/>
                    <measurement group_id="O5" value="12.5" lower_limit="1.6" upper_limit="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Any SAE During Epoch 002</title>
        <description>The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 331 up to and including Day 661, are reported for each group. An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, requires hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician. Epoch 2 data analysis is not achieved at the time of the posting. Results will be added when available.</description>
        <time_frame>From Day 331 up to and including Day 661 (Epoch 002)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Any pIMD's During Epoch 002</title>
        <description>pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Epoch 2 data analysis is not achieved at the time of the posting. Results will be added when available.</description>
        <time_frame>From Day 331 up to and including Day 661 (Epoch 002)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited adverse events were collected during the 7-day follow-up period and unsolicited adverse events during the 30-day follow-up period. Serious adverse events were collected from Day 1 up to Day 331.</time_frame>
      <desc>Other Adverse events were not collected for Shingrix-Only Group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sh_NTHi-Mcat_1 Group</title>
          <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.</description>
        </group>
        <group group_id="E2">
          <title>Sh_NTHi-Mcat_3 Group</title>
          <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.</description>
        </group>
        <group group_id="E3">
          <title>Sh_NTHi-Mcat_6 Group</title>
          <description>Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.</description>
        </group>
        <group group_id="E4">
          <title>NTHi-Mcat Group</title>
          <description>Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.</description>
        </group>
        <group group_id="E5">
          <title>Shingrix-Only Group</title>
          <description>Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHi Mcat investigational vaccine. Only safety data were collected for these subjects.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>COVID-19 pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Peripheral artery restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="125" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling of eyelid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="39" subjects_affected="34" subjects_at_risk="134"/>
                <counts group_id="E2" events="38" subjects_affected="32" subjects_at_risk="134"/>
                <counts group_id="E3" events="34" subjects_affected="26" subjects_at_risk="122"/>
                <counts group_id="E4" events="30" subjects_affected="26" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="50" subjects_affected="40" subjects_at_risk="134"/>
                <counts group_id="E2" events="50" subjects_affected="41" subjects_at_risk="134"/>
                <counts group_id="E3" events="47" subjects_affected="40" subjects_at_risk="122"/>
                <counts group_id="E4" events="31" subjects_affected="26" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="88" subjects_affected="63" subjects_at_risk="134"/>
                <counts group_id="E2" events="114" subjects_affected="78" subjects_at_risk="134"/>
                <counts group_id="E3" events="99" subjects_affected="68" subjects_at_risk="122"/>
                <counts group_id="E4" events="95" subjects_affected="65" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hangover</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="134"/>
                <counts group_id="E2" events="38" subjects_affected="27" subjects_at_risk="134"/>
                <counts group_id="E3" events="34" subjects_affected="28" subjects_at_risk="122"/>
                <counts group_id="E4" events="32" subjects_affected="24" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site movement impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="173" subjects_affected="105" subjects_at_risk="134"/>
                <counts group_id="E2" events="192" subjects_affected="112" subjects_at_risk="134"/>
                <counts group_id="E3" events="157" subjects_affected="98" subjects_at_risk="122"/>
                <counts group_id="E4" events="182" subjects_affected="112" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="134"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="122"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="134"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="122"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial vaginosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Schistosomiasis cutaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="73" subjects_affected="48" subjects_at_risk="134"/>
                <counts group_id="E2" events="80" subjects_affected="64" subjects_at_risk="134"/>
                <counts group_id="E3" events="76" subjects_affected="56" subjects_at_risk="122"/>
                <counts group_id="E4" events="87" subjects_affected="67" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="78" subjects_affected="56" subjects_at_risk="134"/>
                <counts group_id="E2" events="92" subjects_affected="66" subjects_at_risk="134"/>
                <counts group_id="E3" events="59" subjects_affected="44" subjects_at_risk="122"/>
                <counts group_id="E4" events="56" subjects_affected="42" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dental implantation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

